| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
BAY-3827 is a potent and selective inhibitor of AMP-activated protein kinase (AMPK). AMPK is a serine/threonine protein kinase that acts as a cellular energy sensor, activated by increases in the AMP/ATP ratio. Once activated, AMPK phosphorylates downstream targets including acetyl-CoA carboxylase (ACC) and mTOR, regulating fatty acid synthesis, protein synthesis, and autophagy. BAY-3827 inhibits AMPK kinase activity with IC50 values of 1.4 nM at low ATP (10 μM) and 15 nM at high ATP (2 mM). The compound shows over 500-fold selectivity for AMPK over 331 other kinases tested. By inhibiting AMPK, BAY-3827 prevents ACC1 phosphorylation and may affect cancer cell metabolism and proliferation.
|
|---|---|
| ln Vitro |
BAY-3827 (0-200 μM) has been shown to suppress AMPK kinase activity, with an IC50 value of 1.4 nM at low concentrations of 10 μM ATP and 15 nM at high concentrations of 2 mM ATP [1]. At 10 μM ATP concentration, BAY-3827 (0-200 μM) suppresses Flt3, c-Met, Rsk4, Aurora A, and IC50 values of 1324, 124, 788, and 36 nM, respectively [1]. Overnight administration of BAY-3827 significantly lowers the phosphorylation of ACC1 Ser79 in LNCaP and VCaP cells, and to a lesser degree in IMR-32, particularly Colo320 cells [1]. LNCaP and VCaP cells exhibit potent inhibitory effects when exposed to BAY-3827 (0–10 nM; 6 d) [1]. In cells implicated in the production of acylcarnitine in VCaP, BAY-3827 (1 and 5 μM; 24 and 48 hours) suppresses the expression of the LIPE gene, decreases the level of serine/threonine kinase AKT3, and limits the expression of numerous genes of the mitochondrial carnitine palmitoyltransferase (CPT) family [1]. In comparison to androgen-only treatment, BAY-3827 (5 μM; 2-4 d) significantly increases lipid droplet production [1].
BAY-3827 is a potent AMPK inhibitor with IC50 values of 1.4 nM at low (10 μM ATP) and 15 nM at high (2 mM ATP) ATP concentrations. It shows over 500-fold selectivity for AMPK compared to 331 other kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1. The compound exhibits the strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines. It has potential antitumor activity. |
| ln Vivo |
In vivo, BAY-3827 has been evaluated for its antitumor activity in preclinical models, particularly in prostate cancer. The compound shows anti-proliferative activity in an androgen-dependent prostate cancer model. As an AMPK inhibitor, it may affect tumor metabolism and growth. However, detailed in vivo efficacy data are limited. The compound is being investigated for its potential therapeutic applications, particularly in oncology.
|
| Enzyme Assay |
AMPK kinase activity assays are performed using recombinant AMPK enzyme (α1β1γ1 or α2β1γ1 heterotrimer) and appropriate peptide substrates (e.g., SAMS peptide or ACC peptide). The assay typically employs a fluorescence-based or radiometric format to measure kinase activity. BAY-3827 is incubated with the enzyme, substrate, and ATP (at low or high concentration) in assay buffer for 30-60 minutes. The reaction is stopped and product formation is quantified. IC50 values are calculated from concentration-response curves. Selectivity is assessed by screening BAY-3827 against a panel of 331 kinases.
|
| Cell Assay |
Cell proliferation assay[1]
Cell Types: LNCaP, VCaP, 22Rv1, C4-2B, PC-3 and DU-145 prostate cancer cell lines Tested Concentrations: 0-10 nM Incubation Duration: 6 d Experimental Results: For LNCaP and DU-145 prostate Cancer cell lines demonstrated strong inhibitory effects on VCaP cells, two prostate cancer cell lines, with IC50 values of 0.28 and 1.71 nM respectively. Inhibits 22Rv1 cell proliferation with an IC50 value of 5.55 nM. Cellular assays for AMPK inhibition typically employ cancer cell lines, particularly prostate cancer cell lines (androgen-dependent and -independent). Cells are treated with varying concentrations of BAY-3827 for 24-72 hours. AMPK phosphorylation (p-AMPK) and ACC1 phosphorylation (p-ACC1) are assessed by Western blot. Cell viability is assessed using MTT or CellTiter-Glo assays. Cell proliferation is assessed by BrdU incorporation or colony formation assays. The compound's anti-proliferative activity is compared across different cell lines. The effects on cellular metabolism (fatty acid synthesis, autophagy) can be assessed. |
| Animal Protocol |
In vivo efficacy studies with BAY-3827 are typically performed in mouse xenograft models of prostate cancer. Tumor-bearing mice are treated with BAY-3827 orally or intraperitoneally at various doses. Tumor volumes are measured every 2-3 days. Pharmacodynamic markers such as ACC1 phosphorylation are measured in tumor tissues to confirm target engagement. Body weight and clinical signs are monitored for tolerability. The compound's antitumor activity is assessed by tumor growth inhibition.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for BAY-3827 are limited. The compound has molecular formula C27H25FN6O and molecular weight 468.53. It is a small molecule with reasonable membrane permeability. The compound is soluble in DMSO and other organic solvents. For in vivo studies, typical formulations may include DMSO/PEG400/saline mixtures or other suitable vehicles. Standard pharmacokinetic studies would be required for any therapeutic development.
|
| Toxicity/Toxicokinetics |
Toxicological data for BAY-3827 are limited as it is a research compound. As an AMPK inhibitor, potential toxicities may be related to metabolic effects, including altered fatty acid synthesis, protein synthesis, and autophagy. The compound should be handled with appropriate laboratory safety precautions. In preclinical studies, BAY-3827 has been evaluated with acceptable tolerability at the doses used. Standard safety pharmacology studies would be required for clinical development.
|
| References | |
| Additional Infomation |
BAY-3827 is a potent and selective AMPK inhibitor with potential antitumor activity. It shows anti-proliferative activity in an androgen-dependent prostate cancer model. The compound inhibits AMPK kinase activity with over 500-fold selectivity over 331 other kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1. It is being investigated for potential therapeutic applications in oncology.
|
| Molecular Formula |
C27H25FN6O
|
|---|---|
| Molecular Weight |
468.53
|
| Exact Mass |
468.207
|
| CAS # |
2377576-35-5
|
| PubChem CID |
134817183
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
35
|
| Complexity |
977
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NC1C2=C(NN=1)C(C)=C(F)C(C1C(C#N)=C(C)N(C)C(C)=C1C#N)=C2)(=O)C1=CC=CC=C1CC
|
| InChi Key |
OZFFKOSQNBBYCA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H25FN6O/c1-6-17-9-7-8-10-18(17)27(35)31-26-20-11-19(24(28)14(2)25(20)32-33-26)23-21(12-29)15(3)34(5)16(4)22(23)13-30/h7-11,23H,6H2,1-5H3,(H2,31,32,33,35)
|
| Chemical Name |
N-(5-(3,5-dicyano-1,2,6-trimethyl-1,4-dihydropyridin-4-yl)-6-fluoro-7-methyl-1H-indazol-3-yl)-2-ethylbenzamide
|
| Synonyms |
BAY3827 BAY-3827 BAY3827
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~53.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1343 mL | 10.6717 mL | 21.3434 mL | |
| 5 mM | 0.4269 mL | 2.1343 mL | 4.2687 mL | |
| 10 mM | 0.2134 mL | 1.0672 mL | 2.1343 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
